What are the key takeaways from AZN's 2024 earnings performance?

AstraZeneca PLC (AZN) demonstrated strong earnings performance in 2024, with key takeaways including:

1. **Revenue Growth**: AZN's revenue for the quarter ending December 31, 2024, was $14.89 billion. This indicates a robust product sales performance, with cancer drugs and rare disease therapies contributing significantly to the growth.
2. **Earnings Performance**: The company reported earnings per share (EPS) of $0.96 for the most recent quarter. This EPS figure reflects a strong profitability period for AZN, with a notable 17% year-over-year growth in reported earnings.
3. **Analyst Ratings and Targets**: The consensus rating for AZN is a "Strong Buy" with an average analyst price target of $73.79. This suggests that analysts have a positive outlook on the stock, expecting further price appreciation.
4. **Future Earnings Estimates**: While specific estimates for the next fiscal year are not available, the company's historical performance and recent growth suggest that AZN is on track to maintain its earnings momentum.
5. **Market Reaction and Outlook**: Despite the positive earnings report, AZN's stock experienced a decline, possibly due to market adjustments or investor sentiment. However, the company's decision to raise its full-year outlook for 2024 indicates confidence in continued growth, driven by strong demand for its medicines.

In summary, AstraZeneca's 2024 earnings performance highlights its solid financial health and growth potential, supported by positive analyst ratings and a robust product pipeline.